The cluster is driven entirely by mega-passive firms, which may reflect index inclusion or rebalancing rather than active conviction. However, UBS's decision to double down amid price weakness could signal confidence in CABA's clinical pipeline or valuation floor. Traders should monitor upcoming trial data readouts and any shift in active manager positioning.
Executive Summary
Three major passive institutions — Morgan Stanley, Wells Fargo, and UBS — significantly increased their positions in Cabaletta Bio (CABA) during Q4 2024, with UBS doubling its stake and adding $879K in new value. The aggregate buying activity totaled $211K in net new investment, signaling growing institutional interest despite a slight drop in share prices during the period.
Key Financial Metrics
Institutional Positions
Net institutional flow: $211.0K
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | ADD | +73.6% | $3.3M | -$645.2K |
| Wells Fargo | ADD | +67.3% | $92.0K | -$22.3K |
| UBS | DOUBLED | +1808.1% | $986.0K | $879.0K |
Key Facts
- Morgan Stanley increased shares by 73.6% (610.3K shares added), though value decreased by $645K due to falling stock price.
- Wells Fargo added 16.3K shares (+67.3%), with a value decrease of $22K, also indicating price decline during the quarter.
- UBS DOUBLED its position with a massive 1808.1% share increase (411.8K shares added), increasing its stake value by $879K — the strongest conviction move.
- No institutional selling was detected in this quarter, indicating no major exits or loss of confidence.
Financial Impact
Three institutions added a net $211K in new positions, with total holdings now valued at $4.3M. UBS alone drove $879K in value growth, suggesting strong underlying demand despite downward price pressure.
Risk Factors
- All buyers are mega-passive institutions, reducing the strength of the signal — moves may reflect mechanical index flows rather than fundamental conviction.
- Despite share count increases, the total value held by Morgan Stanley and Wells Fargo declined, suggesting CABA's stock price fell during Q4, potentially due to negative sentiment or sector-wide biotech weakness.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-CABA-2024-Q4 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $2.91 $2.46 | ▼ −15.46% | ▼ −15.57% | — |
Aug 15, 2026 6w ago | Institutional Cluster | $2.89 $3.10 | ▲ +7.27% | ▲ +8.46% | — |
Aug 13, 2026 7w ago | 8-K | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | — |
Aug 13, 2026 7w ago | Press Release | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | — |
Jun 11, 2026 16w ago | Institutional Cluster | $3.01 $2.84 | ▼ −5.65% | ▼ −6.32% | — |
Jun 3, 2026 17w ago | 8-K | $3.58 $3.04 | ▼ −15.08% | ▼ −11.26% | — |
Jun 1, 2026 17w ago | DEFA14A | $3.67 $3.25 | ▼ −11.44% | ▼ −8.69% | — |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▼ −2.22% | ▼ −2.93% | — |
May 14, 2026 20w ago | Press Release | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | — |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access